Patients with mantle cell lymphoma (MCL) who were treated with Imbruvica (ibrutinib) had better quality of life (QOL) than those who were gi...
1414
0Like
While immune therapies have revolutionized the treatment of melanoma and other cancers, many patients develop resistance to treatment over t...
1386
0Like
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patient...
1289
0Like
The FDA has granted an accelerated approval to Tecentriq (atezolizumab) as a frontline treatment for patients with locally advanced or ...
1555
0Like
Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a rando...
1179
0Like
Previously treated patients with squamous cell carcinoma of the anal canal (SCCA) saw a 24.3 percent overall response rate (ORR) when treate...
943
0Like
Immunotherapy combination regimens may represent the future of urothelial carcinoma treatment, according to Evan Y. Yu, M.D., as it may be a...
964
0Like
Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC). In ...
1006
0Like
When Susan Thornton developed a rash around her waist she wasn’t sure what to make of it. It was a little itchy, but didn’t hurt...
916
0Like
ClearLLab multicolor reagents (T1, T2, B1, B2, M) gained approval from the Food and Drug Administration (FDA) to detect chronic leukemia, ac...
981
0Like
